"The big news for XENE hit Monday morning, when Xenon announced that its lead epilepsy drug, azetukalner, met the primary endpoint in the Phase 3 X-TOLE2 study for focal onset seizures. The result: a 53.2% reduction in seizure frequency versus placebo. That is the kind of number that turns a speculative biotech into a near-term commercial story."
"This result matters beyond just one trial. Xenon has five active Phase 3 studies across epilepsy and neuropsychiatry, and long-term open-label extension data showed over 90% reduction in monthly focal onset seizure frequency, with over 38% of patients achieving 12 or more months of seizure freedom. That durability of effect is what separates a drug that gets approved from one that actually gets prescribed."
"The company is now targeting an NDA submission to the FDA in the second half of 2026. Cantor Fitzgerald and Stifel both raised their price targets in response, joining a consensus of 21 analysts with Buy or Strong Buy ratings and an average target price of $56.50 heading into today's move."
Xenon Pharmaceuticals (XENE) jumped 49.6% to $62.76 after announcing that azetukalner met its primary endpoint in the Phase 3 X-TOLE2 study, demonstrating a 53.2% reduction in seizure frequency versus placebo for focal onset seizures. The company plans to submit an NDA to the FDA in the second half of 2026. Long-term data showed over 90% reduction in monthly seizure frequency with 38% of patients achieving 12+ months of seizure freedom. Xenon has five active Phase 3 studies and $716 million in pro forma cash with runway into mid-2027. Relmada Therapeutics (RLMD) rose 61.1% to $7.17 following the release of 12-month Phase 2 interim data for NDV-01, its intravesical treatment for non-muscle-invasive bladder cancer.
#biotech-clinical-trials #epilepsy-treatment #bladder-cancer #small-cap-stocks #fda-approval-process
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]